Live
- Gnani’s Gen AI Solutions Revolutionising BFSI
- Trump's WHO threat sparks debate on the efficiency of global health governance
- ICC Champions Trophy 2025 Schedule: India vs Pakistan Match Set for February 23 in Dubai
- Champions Trophy 2025: Full Schedule, Match Dates, Venues, Timings, and Updates
- FRAI Urges Government to Provide Technology Platform for Kirana Stores to Stay Competitive
- Not just Gen Z, millennials too: Redditors discuss the wave of pet parenthood embraced by young Indians
- Innovation can expedite the journey to a Smoke-Free future- in focus at Technovation Abu Dhabi
- Pramod Kumar Voola: Pioneering ethical AI and innovation in healthcare technology
- Rahul Vadisetty: Harnessing AI to revolutionize predictive healthcare
- Interview with Sukumar Bisetty: Driving business transformation with technology
Natco gets CDSCO nod for Covid drug
Natco gets CDSCO nod for Covid drug
Drug major Natco Pharma on Monday said it has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India
New Delhi: Drug major Natco Pharma on Monday said it has received emergency use approval for Baricitinib tablets, for the treatment of Covid-19 positive patients, from the Central Drugs Standard Control Organization (CDSCO) in India.
CDSCO is responsible for approval of drugs, conduct of clinical trials, laying down the standards for drugs, control over the quality of imported drugs in the country and coordination of the activities of state drug control organisations.
"Natco Pharma Ltd has received emergency use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India," the company said in a regulatory filing. Baricitinib in combination with Remdesivir, is used for treatment of Covid-19 positive patients, the company said. Natco said it will request a compulsory license based on emergency use and in light of the grave and serious public health emergency across India due to the pandemic.
The company is ready to launch the product this week, so as to make the product available to suffering patients across India, it added. Shares of Natco Pharma were trading 3.35 per cent higher at Rs 926.70 apiece on BSE.
